Skip to main navigation

Home
News & Events
- News Releases
- Events
Stock Information
Proxy Materials
Corporate Governance
Financials & Filings
- SEC Filings
IR Resources

News Releases

Year

November 14, 2022

Instil Bio Reports Third Quarter 2022 Financial Results and Provides Corporate Update

November 8, 2022

Instil Bio Announces Poster Presentations of CoStAR Platform at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting

October 31, 2022

Instil Bio Announces Voluntary Pause of Enrollment in Ongoing Clinical Trials Related to Manufacturing

October 18, 2022

Instil Bio Announces First Patient Dosed with ITIL-306, our First Engineered TIL Therapy Using the CoStAR Platform Targeting Folate Receptor Alpha (FRα), in Non-Small Cell Lung Cancer

September 19, 2022

Instil Bio to Present at Jefferies Cell and Genetic Medicine Summit

September 9, 2022

Instil Bio to Present at Morgan Stanley Global Healthcare Conference

September 6, 2022

Instil Bio Announces Appointment of Tim Moore as Chief Operating Officer

August 12, 2022

Instil Bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update

May 27, 2022

Instil Bio Announces IND Clearance of First CoStAR-TIL program, ITIL-306, Designed to Enhance Activity in the Tumor Microenvironment

May 18, 2022

Instil Bio to Present Novel TIL Analytics at American Society of Gene and Cell Therapy (ASGCT)

Pagination

Current page 1
Page 2
Next page
Last page

Investor Tools

Instil Bio

Footer Menu

About
Careers
Pipeline
Contact Us
Publications

Site Social Media Links

LinkedIn
Twitter

© 2022 Instil Bio. All Rights Reserved

Privacy Policy Terms of Service Agency Policy